Antibody-drug conjugate · developed by MacroGenics
MGC030 is an antibody-drug conjugate.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07822399 | Phase 1 | Urothelial Cancer | Recruiting | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerEsophageal CancerGastric Cancer (GC)GastroEsophageal CancerPancreatic CancerUrothelial Cancer
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →